Literature DB >> 14514153

CTX-M-3 extended-spectrum beta-lactamase in a Shigella sonnei clinical isolate: first report from Turkey.

Ziya Cibali Acikgoz1, Zeynep Gulay, Meral Bicmen, Safiye Gocer, Sohret Gamberzade.   

Abstract

A Shigella sonnei strain resistant to cefotaxime and aztreonam (but not ceftazidime) was isolated from the stool sample of a 7-y-old outpatient. Double disk synergy test, isoelectric focusing, polymerase chain reaction and sequence analysis confirmed that the isolate produced CTX-M-3, an extended-spectrum beta-lactamase (ESBL). This is the first report from Turkey of Shigella spp. producing an ESBL, and of CTX-M type enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514153     DOI: 10.1080/00365540310013270

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  14 in total

1.  Rapid Increase of CTX-M-Producing Shigella sonnei Isolates in Switzerland Due to Spread of Common Plasmids and International Clones.

Authors:  Edgar I Campos-Madueno; Odette J Bernasconi; Aline I Moser; Peter M Keller; Francesco Luzzaro; Carola Maffioli; Thomas Bodmer; Andreas Kronenberg; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002.

Authors:  Sumathi Sivapalasingam; Jennifer M Nelson; Kevin Joyce; Mike Hoekstra; Frederick J Angulo; Eric D Mintz
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei: First report of plasmid-mediated CMY-2-type AmpC beta-lactamase resistance in S. sonnei.

Authors:  I-Fei Huang; Cheng-Hsun Chiu; Mei-Hui Wang; Chan-Yao Wu; Kai-Sheng Hsieh; Christine C Chiou
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Extended-spectrum beta-lactamase-producing Shigella strains in Israel, 2000-2004.

Authors:  V Vasilev; R Japheth; R Yishai; N Andorn; L Valinsky; S Navon-Venezia; I Chmelnitsky; Y Carmeli; D Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-03       Impact factor: 3.267

5.  Detection of CTX-M-type beta-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru.

Authors:  Lucia Pallecchi; Monica Malossi; Antonia Mantella; Eduardo Gotuzzo; Christian Trigoso; Alessandro Bartoloni; Franco Paradisi; Göran Kronvall; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.

Authors:  Yukiko Nagano; Noriyuki Nagano; Jun-ichi Wachino; Keiko Ishikawa; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  Antimicrobial resistance among Salmonella and Shigella isolates in five Canadian provinces (1997 to 2000).

Authors:  Leah J Martin; James Flint; André Ravel; Lucie Dutil; Kathryn Doré; Marie Louie; Frances Jamieson; Sam Ratnam
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

8.  The occurrence of extended-spectrum β-lactamase producing Shigella spp. in Tehran, Iran.

Authors:  Reza Ranjbar; Farzaneh Mirsaeed Ghazi; Shohreh Farshad; Giovanni Maurizio Giammanco; Aurora Aleo; Parviz Owlia; Nematollah Jonaidi; Nourkhoda Sadeghifard; Caterina Mammina
Journal:  Iran J Microbiol       Date:  2013-06

9.  Clinical and microbiological profiles of shigellosis in children.

Authors:  A V Sangeetha; Subhash Chandra Parija; Iharna Mandal; Sriram Krishnamurthy
Journal:  J Health Popul Nutr       Date:  2014-12       Impact factor: 2.000

10.  Novel extended-spectrum beta-lactamase in Shigella sonnei.

Authors:  Agnes Lefort; Guillaume Arlet; Olivier F Join-Lambert; Marc Lecuit; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.